Aspectos neurobiológicos del trastorno límite de la personalidad y sus implicancias en la impulsividad
aumento de los niveles
aumento de los niveles de testosterona como consecuencia de la aparición de conductas agresivas; y en segundo lugar los estudios llevados a cabo en primates y en humanos no son del todo concluyentes (5, 16). Conclusión Si bien nos hemos focalizado en el estudio de los aspectos neurobiológicos involucrados en la génesis de los síntomas vinculados con el área del control de los impulsos en los pacientes con TLP, una de las principales conclusiones que podemos plantear es el compromiso de múltiples sistemas neurales del SNC y la interacción dinámica entre sí en la producción de dichos síntomas. Será entonces a través de la instrumentación de un proceso psicoterapéutico y psicofarmacológico adecuado en este tipo de pacientes, que podremos lograr una acción sobre diversos sistemas biológicos (sistemas de neurotransmisión, sistemas neurohormonales, mecanismos moleculares y genómicos) encargados de generar muchos de los síntomas presentes en este grupo de pacientes. Finalmente, la complejidad de la neurobiología del cerebro nos aproxima cada vez a la multiplicidad de variables que se presenta en el entendimiento de los trastornos de personalidad, entre ellos el TLP. La constante investigación en el campo de las neurociencias como así también en el campo de la biología y la psicología nos permitirá cada vez más poder disponer de mejores y más eficaces estrategias psicoterapéuticas y psiocofarmacológicas, las cuales re-sultarán en una mejor calidad de vida para este grupo de pacientes. Referencias Bibliográficas 1. Akiskal HS, Chen SE, Davis GC, Puzantian VR, Kashgarian M, Bolinger JM: An adjective in search of a noun. J Clin Psychiatry 1985; 46: 41-48. 2. Andrulonis PA, Glueck BC, Stroebel CF, y cols: Borderline personality subcategories. J Nerv Ment Dis 1982; 170: 670-679. 3. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley S, Reis DJ, Mann J: Autoradiographic demostration of increased serotonin 5-HT 2 and ß adrenergic receptor binding sites in the brain of suicide Arch Gen Psychiatry 1990; 47: 1038-1047. 4. Archer R P, Struve F A, Ball J D, Gordon R A: EEG in borderline personality disorder. Biol Psychiatry 1988; 24: 731-734. 5. Archer J: The influence of testosterone on human agression. Br J Psychol 1991; 82: 1-28. 6. Brown GL, Goodwin FK, Ballenger JC y cols: Agression in humans correlates with cerebrospinal fluid metabolites. Psychiatry Res 1979; 1: 131-139. 7. Brown GL, Ebert MH, Goyer PF, Goyer PF, Jimerson DC, Klein WJ, Bunney WE, Goodwin FK: Agression, suicide, and serotonin relationship to CSF metabolites. Am J Psychiatry 1982; 139: 741-745. 8. Cloninger C R: Temperament and personality. Curr Opin Neurobiol 1994; 4: 266-273. 9. Cocarro EF, Kavoussi RJ, Hauger RL, Coper TB, Ferris CF: Cerebrospinal fluid vasopresin levels correlates with agression and serotonin function in personality disorder subjects. Arch Gen Psychiatry 1998; 55: 708-714. 10. Coccaro EF: Centrlal serotonin and impulsive agression. Br J Psychiatry 1989; 8: 52-62. 11. Coccaro EF, Siever LJ, Kavoussi R, Davis KL: Impulsive agression in personality disorder: evidence for the involvement of 5-HT 1 receptors. Biol Psychiatry 1989; 25(Suppl 7A): 86A. 12. Coccaro E F, Siever L J, Klar H, Maurer G, Cochrane K, Cooper T B, Mohs R C, Davis K L: Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989; 46: 587-599. 13. Coccaro EF, Gabriel S, Siever LJ: Buspirone challenge: preliminary evidence for a role for 5-HT 1A receptors in impulsive agresive behavior in humans. Psychopharmacol Bull 1990; 26: 393-405. 14. Coccaro EF, Kavoussi RJ: Biological and pharmacological aspects of borderline personality disorder. Hosp Community Psychiatry 1991; 42(10): 1029-1033. 15. Coccaro EF, Lawrence T, Trestman R, Gabriel S, Klar HM, Siever LJ: Growth hormone responses to intravenous clonidine challenge correlate with behavioral irritability in psychiatric patients and healthy volunteers. Psychiatry Res 1991; 39: 129-139. 16. Coccaro E F, Siever L J: The Neuropsychopharmacology of Personality Disorders. En: Psychopharmacology: The Fourth Generation of Progress. Ed: Bloom F E, Kupfer D J. Raven Press Ltd, New York 1995; Cap 35: 1567-1579. 17. Coccaro EF, Berman ME, Kavoussi RJ, Hauger RL: Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessment of agression in personality disorder men. Biol Psychiatry 1996; 40:157- 164. 18. Coccaro EF, Kavoussi RJ, Sheline YI, Lisch JD, Csernansky JG: Impulsive-agression in personality disorder. Correlates with 3 H Paroxetine binding in the platelet. Arch Gen Psychiatry 1996; 53: 531-536. 19. Coccaro EF, Kavoussi RJ, Trestman RL, Gabriel SM, Cooper TB, Siever LJ: Serotonin function in human: intercorrelationes among central 5-HT indices and aggressiveness. Psychiatry Res 1997; 73: 1-14. 20. Cornelius J R, Brenner R P, Soloff P H, Schulz S C, Tumuluru R V: EEG abnormalities in borderline personality disorder: specific or nonspecific? Biol Psychiatry 1986; 21: 974-977. 21. Corrigan FM, Davidson A, Heard H: The role of dysregulated amygdalic emotion in borderline personality disorder. Med Hypotheses 2000; 54(4): 574-579. 22. Davidson RJ, Fox N A: Frontal brain asymmetry predicts infants’ response to maternal separation. J Abnorm Psychol 1989; 98: 127-131 23. Davidson RJ, Tomarken A J: Laterality and emotion: an electrophysiological approach. En: Handbook of Neuropsychology. Ed: Boller F, Grafman J. Elsevier, Amsterdam; 1989. 24. Davidson RJ: The Neurobiology of Personality and Personality Disorders. Cap 64: 841-854. En: Neurobiology of Mental Illness. Ed: Charney D S, Nestler E J, Bunney B. Oxoford University Press, New York, 1999. 25. De la Fuente JM, Lostra F, Goldman S, Luxen A, Bidaut L, Stanus E, Mendelewicz J: Temporal glucose metabolism in borderline personality disorder. Psychiatry Res 1994; 55: 237-245. 26. De la Fuente JM, Goldman S, Stanus E, Vizuete C, Morlan I, Bobes J, Mendlewicz J: Brain Glucose metabolism in borderline personality disorder. J Psychiatry Res 1997; 31(5): 531-541. 27. De La Fuente J M, Tugenhaft P, Mavroudakis N: Electroencephalographic abnormalities in borderline personality disorder. Psychiatry Res 1999; 77: 131-138. 28. Drake ME, Philips BB, Paakaluis A: Auditory evoked potentials in borderline personality disorder. Clin Electroencephalogr 1991; 22: 188-192. 29. Dulit RA, Fyer MR, Haas GL, Sullivan T, Frances AJ: Substance use in borderline personality disorder. Am J Psychiatry 1990; 147(8): 1002-1007. 30. Ferris CF, Delville Y: Vasopressin and serotonin interaction in the control of agonistic behavior. Psychoneuroendocrinology 1994; 19: 593-601. 31. Gardner DL, Lucas PB, Cowdry RW: CSF metabolites in borderline personality disorder compared with normal controls. Biol Psychiatry 1990; 28: 247-254. 32. Ghaemi SN, Boiman EE, Goodwin FK: Kindling and second messengers: an approach to the neurobiology of recurrence in bipolar disorder. Biol Psychiatry 1999; 45: 137-144. 33. Gold P W, Goodwin F K, Chrousos G P: Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. N Engl J Med 1988; 314: 348-353 34. Hollander ER, Stein DJ, De Caria CM, Cohen L, Saoud JB, Skodol AE, Kellman D, Rosnick L, Oldham JM: Serotonergic sensitivity in borderline personality disorder: Preliminary findings. Am J Psychaitry 1994; 151: 227-280. 35. Jones B, Heard H, Startup M, Swales M, Willimas JM, Jones RS: Autobiographical memory and dissociation in borderline personality disorder. Psychol Med 1999; 29(6): 1397-1404. 36. Jones E: Vida y Obra de Sigmund Freud. Tomo I: Infancia y Juventud. El autoanálisis. La Interpretación de los Sueños, 1856-1900. Ed. Nova, Buenos Aires; 1959. 37. Jones E: Vida y Obra de Sigmund Freud. Tomo II: Los Años de Madurez 1901-1919. Ed. Nova, Buenos Aires; 1960. 38. Kaplan HI, Sadock BJ, Grebb JA: Synopsis of Psychaitry. En: Personality Disorders, Cap: 26, 727-751. 7 th Ed. Williams & Wilkins, Baltimore, Maryland, USA, 1994. 39. Lucas PB, Gardner DL, Cowdry RW, Pickar D: Cerebral strucutre in borderline personality disorder. Psychiatry Res 1989; 27: 111-115. 40. Lyoo IK , Han MH, Cho DY: A brain MRI study in subjects with borderline personality disorder. J Affect Disord 1998; 50(2-3): 235-243. 41. Mann JJ, Malone KM, Diehl DJ, y cols: Demostration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry 1996; 153: 174-182. 42. Miller FT, Abrams T, Dulit R, Fyer M: Substance Abuse in Borderline Personality. Am J Drug Alcohol Abuse. 1993; 19(4): 491-497. 43. Moss HB, Yao JK, Panzak GL: Serotonergic responsitivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry 1990; 28: 325-338. 44. Murphy D L, Aulakh C, Mazzola-Pomietto P, Briggs N C: Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: A preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measure. Behav Brain Res 1996; 73: 209-214. 45. Ogiso Y, Moriya N, Ikuta N, Maher-Nishizono A, Takase M, Miyake Y, Minakawa K: Relationship between clinical symptoms and EEG finding in borderline personality disorder. Japanese Journal of Psychiatry 1993; 47: 37-46. 46. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM: Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 1990; 28: 215-222. 47. Pope HG, Jonas JM, Hudson JL, y cols: The validity of DSM III borderline personality disorder: a phenomenological, family history, treatment response, and long term follow up study. Arch Gen Psychiatry 1983; 40: 23-30. 48. Post RM, Uhde TW, Putnam FW, Ballenger JC, Berrettini WH: Kindling and carbamazepine in affective illness. J N Ment Dis 1982; 170: 717-731. 49. Raine A, Buchsbaum M, Stanley J, Lottenberg S, Abel L, Stoddard J: Selective reduction in prefrontal glucose metabolism in murderers. Biol Psychiatry 1994; 36: 365- 373. 50. Rinne T, Westenberg HT, den Boer JA, ven den Brink W: Serotonergic blunting to meta-clorophenylpyperazine (m-CPP) highly correlates with sutained childhood abuse in impulsive and autoagressive female borderline patients. Biol Psychiatry 2000; 47(6): 548-556. 51. Saudou F, Ait Amara D, Le Meur M, Ramboz S, Segu L, Buhot M y cols: Enhanced aggressive behavior in mice lacking the 5-HT 1B receptor. Science 1994; 265: 1875- 1878. 52. Siever LJ, Buchsbaum MS, New AS, y cols: d,l-fenfluramine response in impulsive personality disorder assessed with glucose [ 18 F] fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 1999; 20: 413-423. 53. Simeon D, Stanley B, Frances A, Mann JJ, Winchel R, Stanley M: Self mutilation in personality disorders: Psychological and biological correlates. Am J Psychaitry 1992; 149(2): 221-226. 54. Soloff PH: A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry 2000; 47(6): 540-547. 55. Soloff PH: Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 2000; 23(1): 169- 192. 56. Stolk J M, Conner R L, Levine S, Barchas J D: Brain norepinephrine metabolism and shock-induced fighting on the neurochemical response to a common footshock stimulus. J Pharmacol Exp Ther 1984; 190: 193-209. 57. Stoll AL, Severus WE: Mood stabilazers: shared mechanism of action at postsynaptic signal-transduction and kindling process. Harv Rev Psychiatry 1996; 4(2): 77-89. 58. Sutton S K, Davidson R J: Prefrontal brain asymmetry: a biological substrate of the behavioral approach and inhibition systems. Psychol Sci 1997; 8: 204-210 59. Tomarken A J, Davidson A J, Wheeler R E, Doss R C: Individual differences in anterior brain asymmetry and fundamental dimensions of emotion. J Pers Soc Psychol 1992; 62: 676-687. 60. Van Reekum RP: Acquired and developmental brain dysfunction in borderline personality disorder. Can J Psychiatry 1993; 38(Suppl): S4-S10. 61. Verkes RJ, Van der Mast RC, Kerkhof Ad JFM, Fekkes D, Hengeveld MW, Tuyl JP, Van Kempen GMJ: Platlet serotonin, monoamine oxidase activity, and [ 3 H] Paroxetine binding related to impulsive suicide attemps and borderline personality disorder. Biol Psychiatry 1998; 43: 740-746. PSICOFARMACOLOGÍA // 21
